Verywell Health on MSN

Understanding Hypovolemia

Medically reviewed by Kashif J. Piracha, MD Key Takeaways Hypovolemia is a severe loss of body fluids and can lead to organ ...
Business Wire

Vivacelle Bio’s VBI-S Phase IIa Clinical Trial Meets Primary and Secondary Endpoints for Treating Hypovolemia in Septic Shock Patients

KANSAS CITY, Mo.--(BUSINESS WIRE)--Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic ...
KELOLAND News

Vivacelle Bio Enrolls First Patient in Phase 3 Trial of Hypovolemia Due to Septic Shock for Phospholipid Nanoparticle-Based VBI-S

KANSAS CITY, Mo., Sept. 3, 2024 /PRNewswire/ -- Vivacelle Bio, a late-stage biopharma company developing life-saving treatments for shock and trauma, today announced that it has enrolled the first ...
Nasdaq

Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India

Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a ...
Longview News-Journal

Vivacelle Bio Enrolls First Patient in Phase 3 Trial of Hypovolemia Due to Septic Shock for Phospholipid Nanoparticle-Based VBI-S

"I congratulate our team on enrolling the first patient in our Phase 3 trial for VBI-S, our lead asset built on Vivacelle's patented phospholipid nanoparticle technology, which is designed to restore ...